The Bundibugyo Strain: A Rare but Deadly Threat

Oxford University scientists are working against the clock to develop a vaccine for the Bundibugyo strain of Ebola,a rare but deadly threat that has already claimed 177 lives in the Democratic Republic of the Congo.

The outbreak, which has resulted in 750 suspected cases, has been upgraded to a 'very high' risk by the World Health Organisation (WHO), with the virus spreading rapidly in the country.

The WHO has declared a public health emergency of international concern, stressing that the outbreak is not a pandemic but a serious threat that requires immediate attention.

From Covid-19 to Ebola: The Same Technology, New Challenge

The Oxford Vaccine Group (OVG) is using the same technology that underpinned its Covid-19 jab to develop a vaccine for the Bundibugyo strain of Ebola.

The technology has shown promise in combatting Covid-19, and the OVG is hopeful that it will be equally effective in tackling the Ebola outbreak.

However, the development of a vaccine is a complex and time-consuming process, and it remains to be seen whether the OVG will be able to deliver a life-saving vaccine in time.

What We Still Don't Know

Despite the urgent need for a vaccine, there are still many unanswered questins about the outbreak.

For example,the WHO has reported that the virus is spreading rapidly in the Democratic Republic of the Congo,but it is unclear how the outbreak will affect the wider region.

The WHO has also stresed that the outbreak is not a pandemic, but it remains to be seen whether this assessment will hold true in the coming weeks and months .